Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Innate Pharma SA

IPHA ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.01

▲ +8.65%

Market Cap $201.19M · Vol 42.48K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$201.19M

Micro Cap

Div Yield

N/A

EPS Growth

-12.08%

YoY

RSI (14)

39.73

Momentum

Beta

0.68

vs Market

52W High

$2.71

25.83% below

52W Low

$1.17

71.79% above

Volume

42.48K

Avg 53.72K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

98.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Innate Pharma SA (IPHA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IPHA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.08%

-7.80%

+12.29%

+42.55%

YTD

+14.86%

-3.37%

-32.78%

-65.04%

Financials & Valuation

TTM · Annual

Total Revenue	$3.27M
Net Income	$-57,758,125.00
Revenue Growth (YoY)	-74.22%
Gross Margin	1.29%
Operating Margin	-1,834.19%
Net Profit Margin	-1,764.51%
ROE	N/A
ROA · ROIC	-56.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	47.90
P/B	N/A
P/FCF	N/A
EPS Growth	-12.08%
Outstanding Shares	111.72M

Technical Indicators

50-Day SMA	$1.97
200-Day SMA	$1.75
RSI (14)	39.73
Beta	0.68
52-Week High	$2.71
52-Week Low	$1.17

Volume Today	42.48K
Avg Daily Volume (30D)	53.72K
Relative Volume	0.79x
Volatility (10D)	56.16
Volatility (30D)	110.72
Free Float	98.60%

Analyst Consensus

BUY

Current Price $2.01

Mean Target $7.13

52W Low$1.17 52W High$2.71

Current

Target

$1.17 $2.71

Current Analyst target

+254.69% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG009ZCBWH4

ISINUS45781K2042

CountryFrance

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

LONN.S Lonza Group AG +0.22% ONC BeOne Medicines AG +0.46% 068270.KS Celltrion, Inc. -0.17% MEDP Medpace Holdings, Inc. -0.65% ABVX Abivax SA -4.15%

Company Profile

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.